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Abstract
Background Pulmonary hypertension (PH) is the most
important complication of congenital diaphragmatic hernia
(CDH) and still has a high mortality rate. The aim of this
study was to evaluate the effectiveness of inhaled nitric
oxide therapy in PH due to CDH.
Methods Hospital records of children who had undergone
inhaled nitric oxide therapy for PH due to CDH between
June 2009 and December 2011 were reviewed.
Results Twenty-nine patients had a diagnosis of CDH at
the time of study, and eight of these patients underwent
nitric oxide therapy because of failure of conventional
ventilation techniques, which was successful in five of
these patients. Patients who had a good overall outcome of
nitric oxide therapy experienced rapid improvement (pre-
treatment, mean PaO2 = 44.8 mmHg; after the first hour of
therapy, mean PaO2 = 96.8 mmHg), whereas patients with
no response did not have a similar course (pretreatment,
PaO2 = 37 mmHg; after the first hour, PaO2 =
54.6 mmHg).
Conclusion Inhaled nitric oxide therapy seems to
increase survival in PH due to CDH. No predictive
parameters to orient patient selection could be identified;
however, the early response seemed to predict the overall
outcome. Good results in our series were attributed to
routine use of sildenafil and dopamine, along with the nitric
oxide inhalation.
1 Introduction
Nitric oxide is a potent vasodilator, which acts through
guanylyl cyclase activation, leading to production of cyclic
guanosine monophosphate and therefore smooth muscle
relaxation [1]. Inhaled nitric oxide (iNO) serves as the only
selective pulmonary vasodilator available today, and sev-
eral studies have shown that it improves the outcome of
newborns with pulmonary hypertension (PH) [2–8].
Although PH due to congenital diaphragmatic hernia
(CDH) has been suggested to have a similar pathophysio-
logical mechanism, published results of iNO therapy in
such cases have not been as good as expected. The only
randomized trial [9] failed to show any benefit and, despite
widening usage of this therapy, the literature still consists
of conflicting reports [10–18]. The aim of this study was to
evaluate our results with iNO therapy for PH due to CDH.
2 Patients and Methods
Hospital records of children who had undergone iNO
therapy for PH due to CDH from June 2009 to December
2011 were reviewed. As a part of our institution’s protocol
for CDH, all patients with signs of PH were intubated, and
bedside central venous catheterization and umbilical arte-
rial catheterization were performed immediately. Dopa-
mine infusions (5 lg/kg/min) and sildenafil (0.5 mg four
times daily, administered enterally via the nasogastric tube)
were started. Our initial management includes pressure-
controlled ventilation in the synchronized intermittent
mandatory mode, adhering to the concept of gentle venti-
lation with permissive hypercapnia in CDH. This involves
keeping pressure settings at the lowest levels (peak inspi-
ratory pressure [PIP] \25 mmHg), providing a partial
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pressure of arterial oxygen (PaO2) higher than 70 mmHg
and a partial pressure of arterial carbon dioxide (PaCO2)
lower than 70 mmHg, keeping the blood pH over 7.20. A
positive end-expiratory pressure (PEEP) of 4–5 mmHg was
used in all patients. High-frequency oscillatory ventilation
in patients with CDH due to former poor results in our
clinic and due to lack of an extracorporeal membrane
oxygenation (ECMO) machine at our centre or at any
nearby centre to deliver the patient to at the time of this
study, iNO was the therapy chosen for patients with failure
of conventional therapy. iNO therapy was applied to
patients with clinical signs of PH ([10 % pre-postductal
difference in pulse oximetry screening), hypoxemic respi-
ratory failure despite optimal conventional ventilation
(PaO2 \80 mmHg on 100 % fraction of inspired oxygen
[FiO2] with optimal lung inflation), and a systolic pul-
monary arterial pressure (PAP) higher than 40 mmHg (all
patients were evaluated with echocardiography). iNO was
used for both early and late PH. Parental consent was
obtained before initiation of the therapy. NOxBOX (Bed-
font Scientific, Maidstone, UK), which is a machine able to
deliver constant concentrations of NO via a non-rebreath-
ing circuit and continuous flow, was used for iNO appli-
cation. Continuous monitoring of NO and NO2
concentrations was performed via an electrochemical
scanner, and a nitrogen dioxide level below 2 parts per
million (ppm) was considered acceptable. Methemoglobin
levels were also monitored continuously, using SpMet
Radical-7R (Masimo Corporation, Irvine, CA, USA), and a
value over 1 % was never detected. iNO was started at a
dosage of 20 ppm and raised up to a maximum dosage of
45 ppm. iNO was ceased after weaning gradually to a
dosage of 10 ppm as the blood gases improved. The sil-
denafil and dopamine dosages remained the same
throughout the therapy, and were stopped at the same time
as iNO. All surviving patients had transfontanelle cranial
ultrasonography, audiological assessment, retinal exami-
nation, and echocardiography to detect possible side effects
of iNO before discharge. All patients received close fol-
low-up; the mean follow-up duration was 38 (27–52)
months.
Approval was obtained for retrospective review of the
hospital records from the local ethics committee. To
evaluate the success of iNO therapy, individual character-
istics of the patients, ventilation parameters, and blood gas
parameters were reviewed, and respiratory indices (the
oxygenation index [OI] and the alveolar–arterial oxygen
difference [AaDO2]) were computed and assessed with the
outcome. Statistical analyses were performed using a Stu-
dent’s t test and a Mann–Whitney U test because of the
small number of patients, and any results with a p value
less than 0.05 were considered statistically significant.
3 Results
Twenty-nine patients had a diagnosis of CDH at the time of
study. Eight of these patients underwent nitric oxide ther-
apy because of failure of conventional ventilation tech-
niques, and five of these eight applications were successful.
Considering the patients who underwent iNO therapy, the
mean gestational age was 38 (36–40) weeks, and the mean
birth weight was 3,058 (2,290–3,950) g. Two patients did
not receive an antenatal diagnosis of CDH, the others were
diagnosed at 16–38 weeks of gestation (with a median of
24 weeks). One of the patients (who was diagnosed at
16 weeks of gestation) had an unsuccessful application of
fetoscopic tracheal occlusion, and termination of preg-
nancy was offered to the parents in another clinic. Six
patients had left-sided hernias, and two had right-sided
hernias. There was stomach herniation in four patients and
liver herniation in three. All patients were operated upon
when they were hemodynamically stabilized and could
maintain an optimal blood gas level, with FiO2 \40 % and
PIP \25 mmHg. The mean timing of the operation was
3.75 days (2–7 days). Six patients underwent preoperative
application of the therapy (at 0–1 day), and two patients
underwent late application of the therapy (at 9–12 days).
The mean systolic PAP was 52.5 mmHg (43–70 mmHg)
before initiation of the therapy. None of the patients had
structural congenital heart disease that might have cause
intracardiac shunting (Table 1). Both patients with late PH
were found to have a good response, whereas the patients
with low birth weights were unresponsive to iNO therapy
(Table 2); however, our patient group was too small to
attribute a predictive feature to these variables regarding
the success of the therapy.
All patients had deficient oxygenation despite optimal
ventilatory support (mean PaO2 = 46 mmHg). Before
application of iNO, the mean AaDO2 was 555 (470–618)
and the mean OI was 41.12 (14–62). No hypotension was
observed during the therapy. The OI decreased by a mean
of 7.6 and the PaO2 increased by a mean of 36 mmHg
within 60 min of commencing therapy. After cessation of
the therapy, the mean PaO2 was 94.4 mmHg (70–108), the
mean AaDO2 was 141.6 (72–289), and the mean OI was
5 (3–8) (Table 2). The initial respiratory status of the
patients did not seem to predict their response to iNO
therapy (p = 0.14 for PaO2, p = 0.16 for AaDO2, and
p = 0.49 for OI); however, patients who had a good overall
outcome were found to have rapid improvement after the
first hour of therapy (pretreatment, mean PaO2 =
44.8 mmHg; after the first hour of therapy, mean
PaO2 = 96.8 mmHg), whereas patients with no response
did not show a similar course (pretreatment, mean PaO2 =
37 mmHg; after the first of hour of therapy, mean
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PaO2 = 54.6 mmHg) [p = 0.04 for PaO2 and p = 0.03 for
OI] (Table 2).
Except for the patient with a history of fetoscopic tra-
cheal occlusion, all surviving patients were extubated, were
discharged without oxygen dependency, and required no
further therapy for PH after cessation of iNO. That par-
ticular patient, who had a number of risk factors with his
history of unsuccessful fetoscopic tracheal occlusion, a
right diaphragmatic hernia, a lung-to-head ratio of 0.8, and
a PAP of 70 mmHg, underwent a tracheotomy and was
discharged with a home ventilator. He was able to come off
the ventilator at 16 months of age, and his tracheotomy was
closed at 21 months. Even that patient was described as
having normal neurological development by his parents.
Another point worth mentioning is the safety of this
therapy. No evidence of any short- or long-term adverse
effects of iNO were observed. There was no sign of
intraventricular hemorrhage on transfontanelle ultrasonog-
raphy or retinopathy on retinal examination. The mean
PAP was 28 mmHg (25–32 mmHg) on echocardiography
before discharge, and no patent ductus arteriosus was
detected. Audiological assessment was also performed, and
no hearing impairment (defined as a threshold of more than
40 dB) was detected. Special neurodevelopmental tests
were not applied to these patients; however, none of the
patients’ parents reported any developmental delay, and
there was no history of seizures.
4 Discussion
PH is one of the most important aspects of CDH and still
has a high mortality rate. Several studies have documented
that iNO improves PH with causes other than CDH in
newborns [2–8]. The Neonatal Inhaled Nitric Oxide Study
Group trial also showed that iNO decreases the need for
ECMO in patients with PH not caused by CDH [5], without
any increase in neurodevelopmental impairment at 2 years
of age [6]. There are no published data demonstrating why
iNO therapy may not work in patients with CDH, yet
findings concerning CDH are inconsistent through the lit-
erature [9–11, 14]. Also, despite the results of the ran-
domized trial, the Congenital Diaphragmatic Hernia Study
Group reported that there has been a change in the man-
agement of infants with CDH, with less frequent use of
ECMO and greater use of iNO [11]. An easy and potent
therapy such as iNO would be very valuable if it works for
this major determinant of survival in patients with CDH.



















1 35 40 3,400 Left Thorax 1 45 Alive
2 38 39 3,950 Left Abdomen 9 50 Alive
3 17 38 3,070 Left Abdomen 0 52 Alive
4 16 36 3,100 Right Abdomen 0 70 Alive
7 20 37 3,150 Left Thorax 12 55 Alive
5 None 38 2,290 Left Thorax 1 50 Exitus
6 16 36 2,400 Left Thorax 0 55 Exitus
8 None 40 3,100 Right Abdomen 0 43 Exitus
CDH congenital diaphragmatic hernia, iNO inhaled nitric oxide, PAP pulmonary arterial pressure
Table 2 Oxygenation parameters before inhaled nitric oxide (iNO) therapy, after 1 hour of therapy, and after cessation of therapy
Patient number Before therapy After 1 hour of therapy After cessation of therapy
PaO2 AaDO2 OI PaO2 OI PaO2 AaDO2 OI
1 74 567 14 88 20 108 72 4
2 45 601 44 64 34 102 145 5
3 45 586 56 159 14 106 69 3
4 47 512 40 83 32 86 289 8
7 43 618 37 90 24 70 133 5
5 45 470 36 40 72 Exitus
6 26 568 62 44 67 Exitus
8 40 518 40 80 45 Exitus
AaDO2 alveolar–arterial oxygen difference, OI oxygenation index, PaO2 partial pressure of arterial oxygen
Initial Oxygenation Response 217
We are certainly unable to claim definite conclusions with
this retrospective study on a small patient group. The mean
AaDO2 of the group was 555, and the mean OI was 41.
Considering the association of an AaDO2 score higher than
580 and a OI score higher than 40 with a mortality rate of
80 % [19], the mortality rate of 37.5 % seems to have been
a relatively good outcome for this patient group.
Our patient group was too small for us to claim a
reduced mortality rate in CDH patients; however, we
would like to emphasize two important points that drew our
attention.
The first was that, in line with the findings of previous
reports, there was a strict and immediate distinction within
the first hour of therapy between patients who would and
those who would not subsequently benefit from it. Con-
sidering this early response and the more than 50 %
reduction in the mortality rate, we think that iNO therapy
could be a first-line treatment option, with ECMO (which is
a much more invasive and expensive therapy and is asso-
ciated with a high complication rate) being reserved for use
as an alternative if iNO therapy fails. In our opinion, 1 hour
of delay would not hinder transfer to ECMO, and a short
trial of iNO therapy is definitely worthwhile before
exposing newborns to the risks of ECMO, in order to
provide newborns with a safer treatment option.
The second point we wanted to draw attention to is that
on reviewing our results and the literature, we thought that
details of the various institutions’ protocols might explain
the inconsistent results reported in the literature. In dif-
ferent studies, better outcomes have been attributed to
usage of cathecolamine [10] and sildenafil [2] individually.
Our treatment protocol involved inotrope and sildenafil
usage in all patients, which led us to speculate that it might
have explained our better results. Both inotropes and sil-
denafil have been used in our clinic since before iNO
therapy was introduced for PH in patients with CDH.
Dopamine has been used to augment cardiac performance,
and sildenafil has been used for pulmonary vasodilatory
effects. It has been suggested that decreased left ventricular
performance is common and may be an important deter-
minant of responsiveness to iNO therapy in CDH [8].
Shiyanagi et al. [10] reported better results when they
switched their therapy from prostaglandins to cathechol-
amines in addition to iNO. Keller et al. [20] reported better
results with use of iNO and phosphodiesterase inhibition.
We think that use of dopamine (which augments left ven-
tricular performance) and sildenafil (which has pulmonary
vasodilator effects) might increase the response to iNO
therapy; therefore, we attribute the reduction in the mor-
tality rate to our institution’s protocol involving use of
dopamine and sildenafil together. We do not have enough
data to confirm this statement; however, it might be the key
to the conflicting results of studies involving iNO usage in
CDH, and it deserves further attention.
5 Conclusion
The early response to iNO therapy in patients with PH due
to CDH seemed to predict the overall outcome; therefore, a
‘‘short trial’’ of iNO therapy should be considered as the
first-stage option before subjecting newborns to ECMO.
Institutional protocol differences might be the cause of the
conflicting findings reported in the literature, and this
requires further investigation.
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